Analysis on medication and clinical pathway medication recommendation in inpatients with cerebral infarction

Na WANG,Rong-sheng ZHAO,Lu-lu SUN
DOI: https://doi.org/10.3969/j.issn.1672-3384.2016.02.011
2016-01-01
Abstract:Objective: To analyze and recommend medication in inpatients with cerebral infarction (CI).Methods:Via retrospective study method, medication analysis in inpatients with CI, and recommendations on clinical pathway were based on the guidelines and so on.Results:About 89% of patients with CI have two or more diseases. The top 5 drugs for the treatment are aspirin, atorvastatin calcium, Danhong, edaravone and cinepazide. Irrational drug use ratio is 9.93%, and the top 3 ones are inappropriate usage and administration route, no special reason for medication in compliance with the guidelines and no indication. The average cost of medicine was 11 100 yuan/person, accounting for 49.33% of the total cost.Conclusion: Various kinds of medications were used for the treatment of inpatients with CI, however the rationality of some drugs lacks evidence-based support. We should optimize clinical pathway medication regimensin order to improve medication cost-effectiveness.
What problem does this paper attempt to address?